News
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...
Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
11hon MSN
JACKSON, Miss. (WLBT) -A new breakthrough drug for HIV Prevention has been approved by the FDA. The drug is called “Yeztugo” ...
While Gilead Sciences' HIV prevention drug lenacapavir got approved by the US Food and Drug Administration (FDA), its made- ...
The United States Food and Drug Administration (FDA) has approved Lenacapavir (LEN), a long-acting injectable antiretroviral hailed as a breakthrough in HIV prevention. Experts in India have welcomed ...
Discover how mRNA vaccines could revolutionize medicine by targeting 9 major diseases. Learn about breakthrough treatments ...
18h
Everyday Health on MSNFDA Approves a ‘Game-Changing’ Twice-a-Year HIV Prevention ShotThe new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or every-other-month injections.
The Wistar Institute has launched its HIV Cure and Viral Diseases Center with new lab space on Market Street and a plan to ...
The U.S. Food and Drug Administration has approved a groundbreaking HIV prevention shot that only needs to be taken twice a year. Medical experts are calling it one of the most significant ...
21h
The New Times on MSNWHO guidelines for 6-month HIV prevention drug to be released in KigaliThe approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results